Understanding Metabolic Associated Fatty Liver Disease in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a long-term cohort of patients diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) or non-alcoholic fatty liver disease (NAFLD) in China. It will involve a cross-sectional analysis to collect clinical data and a follow-up to gather plasma, urine, and stool samples from participants. The goal is to identify biomarkers that can help in patient stratification and predict disease prognosis, thereby enhancing understanding of liver-related complications associated with these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed as hepatic steatosis in adults (fulfill at least one of the followings):

  1. Liver ultrasound shows liver parenchymal hyperechoic or "bright liver"
  2. Controlled attenuation-parameter (CAP) ≥248dB/m
  3. Hepatic steatosis diagnosed by CT/MRI/MRS
  4. MRI-based proton-density fat fraction (MRI-PDFF) shows liver fat content\>8%
  5. Fatty liver confirmed by liver histology.

Exclusion Criteria:

1. Diagnosed with hepatocellular carcinoma or other malignancy (in accordance with the appropriate diagnostic criteria);
2. During pregnancy;
3. Patients with history of liver transplantation;
4. Patients with serious cardiovascular and cerebrovascular events (such as acute myocardial infarction, cerebral infarction, cerebral hemorrhage, etc.).

Where it's running

• Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Jinjun Chen
• Email: chjj@smu.edu.cn
• Phone: 8618588531001

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glucagon resistance in MASLD and type 2 diabetes

  This will see if people with type 2 diabetes, with or without MASLD, respond differently to glucagon in liver fat oxidation and VLDL-triglyceride secretion.

  Recruiting University of Aarhus · Aarhus · NCT07246421

• Rifaximin treatment for metabolic-associated fatty liver disease

  This trial tests whether taking oral rifaximin for 24 weeks helps adults with metabolic-associated fatty liver disease (MAFLD) and is safe.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07185932

• New MRI methods to measure metabolism and predict outcomes in metabolic-associated fatty liver disease

  This project tests whether new MRI techniques can measure body metabolism and help predict disease status and prognosis for people with metabolic-associated fatty liver disease.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07149571

• Non-invasive blood and imaging tests for metabolic liver disease

  This project tests whether blood tests and imaging scans can diagnose and stage metabolic-associated steatohepatitis (MASH) and liver fibrosis in adults with metabolic risk factors.

  Recruiting at 4 sites Foundation for the National Institutes of Health · Miami, Florida and 3 other locations · NCT07122700

• Effects of a Low Valine Diet on Weight and Metabolism

  This study is testing if meal replacements with less valine can help overweight and obese people lose weight and improve their metabolism compared to regular meal replacements.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06883578

• Investigating the prevalence of metabolic associated fatty liver disease in patients with type 2 diabetes in Jiangsu Province, China

  This study looks at how common fatty liver disease is in people with type 2 diabetes in Jiangsu Province, China, and how it relates to their insulin levels.

  Recruiting Wuxi Hisky Medical Technology Co Ltd · Nanjing, Jiangsu · NCT05597709

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.